KNB Kanabo Group Plc

TIDMKNB

RNS Number : 3645A

Kanabo Group PLC

23 May 2023

23 May 2023

Kanabo Group plc

("Kanabo", the "Company")

Issuance of New Ordinary Shares to Advisers and Service Providers

Kanabo Group plc (LSE: KNB) , the patient focused healthcare technology and medicinal cannabis company, announces the issuance of 1,080,247 new ordinary shares to advisers and service providers. Further details can be found below.

Asserson Shares

Asserson Law Offices ("Asserson") will be issued with 743,055 new ordinary shares ("Asserson Shares") at a price of 6.06 pence per share. These shares will be issued as payment for outstanding invoices.

4LLC Shares

The 4th Consulting LLC ("4LLC") will receive 5,000,000 shares at a price of 3.01 pence as part of a settlement agreement entered between Kanabo, Luca Longobardi, and 4LLC ("4LLC Settlement Agreement"). The shares will be issued for the provision of brokerage services in relation to the acquisition of The GP Service ("GPS"). 4LLC will receive their shares in two tranches, with 3,000,000 shares ("First Tranche") to be received immediately and the remaining 2,000,000 shares ("Second Tranche") to be received within the next three months.

Of the First Tranche, 337,192 new ordinary shares ("4LLC Shares") will be issued by the Company immediately. The remaining 2,662,808 ordinary shares of the First Tranche will be transferred from the shares previously held by Atul Devani, Co-founder of GPS. As announced in September 2022, Mr Devani signed a compromise agreement on leaving the Company under which he returned 25% of the shares received as consideration for the acquisition of GPS. As such, in settlement of the First Tranche the Company will be issuing 337,192 new ordinary shares only.

In relation to the Second Tranche, the Company will make an announcement in due course.

The 5,000,000 shares are all subject to a simple orderly market agreement. Thereby, recipients of the shares will inform Kanabo or their broker of their intention to dispose of any shares, giving the Company or their broker the opportunity via its broker to place the shares. In the event it is not possible for Kanabo or their broker to place the shares, the seller can dispose of the shares.

Admission to trading

Application has been made to the London Stock Exchange for the new ordinary shares to be admitted to trading on the Standard List of the London Stock Exchange ("Admission"). Admission is expected to occur at 8.00 a.m. on or around 26 May 2023. The shares will rank pari passu with the Company's existing Ordinary Shares.

Total voting rights

Following Admission, the Company's enlarged issued share capital will be 500,385,193 Ordinary Shares. This figure of 500,385,193 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

 
Kanabo Group plc                                       via Vigo Consulting 
 Avihu Tamir, Chief Executive Officer                   +44 (0)20 7390 0230 
 Assaf Vardimon, Chief Financial Officer 
 Ian Mattioli, Non-Executive Chair of the Board 
Peterhouse Capital Ltd (Financial Adviser 
 and Broker) 
 Eran Zucker / Lucy Williams / Charles Goodfellow      +44 (0)20 7469 0930 
 
Vigo Consulting (Financial Public Relations/Investor 
 Relations) 
 Jeremy Garcia / Fiona Hetherington / Verity 
 Snow                                                   +44 (0)20 7390 
 kanabo@vigoconsulting.com                               0230 
 

About Kanabo Group Plc

Kanabo Group Plc (LSE:KNB) is a healthtech company committed to revolutionising patient care through its innovative technology platform and disruptive product offerings. Since its inception in 2017, Kanabo has been focused on researching, developing, and commercialising regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.

Kanabo's NHS-approved online telehealth platform, The GP Service, provides patients with video consultations, online prescriptions, and primary care services. The Company is a leader in its field, focusing on improving patient outcomes and providing more accessible healthcare experiences.

In March 2023, Kanabo successfully launched its Pain Clinic, Treat It, under the expert guidance of its technological and product expertise. Treat It initially focuses on chronic pain management using plant-based medicine and treatments that are currently unavailable through traditional channels.

At Kanabo Group Plc, we are dedicated to providing patients with the highest quality medical treatments and more accessible healthcare experiences.

Visit www.kanabogroup.com for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEPPUMAAUPWUBW

(END) Dow Jones Newswires

May 23, 2023 06:00 ET (10:00 GMT)

Kanabo (LSE:KNB)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Kanabo (LSE:KNB)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024